Recent advances in neuroproteomics and potential application to studies of drug addiction.
The rapidly growing field of proteomics seeks to track changes in protein expression function that underlie the growth and differentiation of individual cell types, both during normal development and during the onset and progression of disease. Recent years have seen great strides in mRNA expression analysis, and the development of new technologies for protein profiling. However, current methods are limited to analysis of the relative expression level of only a few hundred to perhaps 2000 proteins, well below the ability of DNA microarrays to potentially interrogate the mRNA expression of more than 25,000 genes. Proteomics faces a special challenge in studies of the nervous system, where cellular and sub-cellular architecture is among the most complex in the body. This article presents an overview of current proteomic profiling technologies, reviews the recent use of some of these approaches in studies of the nervous system, and discusses the potential application of neuroproteomics to studies of drug addiction.
Department of Molecular Biophysics and Biochemistry, Boyer Center for Molecular Medicine Yale University School of Medicine, 295 Congress Avenue, New Haven, CT 06536-0812, USA.
Kenneth
K
Williams
Terence
T
Wu
Christopher
C
Colangelo
Angus C
AC
Nairn
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects / Q000235:genetics; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D013058:Mass Spectrometry; D009479:Neuropeptides / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D009488:Neurosciences / Q000639:trends*; D010750:Phosphoproteins / Q000378:metabolism; D040081:Protein Array Analysis; D011499:Protein Processing, Post-Translational; D040901:Proteomics / Q000639:trends*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D019966:Substance-Related Disorders / Q000235:genetics*
D009479:Neuropeptides; D010750:Phosphoproteins